Xcout IntelHealome Therapeutics competitors & alternatives
The 12 closest competitors and alternatives to Healome Therapeutics among healthcare companies — ranked by similarity to what Healome Therapeutics actually does, not by market-cap band.
Subscribe to see Healome Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Healome Therapeutics
Healome Therapeutics is an eye care therapeutics company headquartered in Birmingham, United Kingdom. The company focuses on developing more effective, safer, and practical treatments for vision-threatening ocular surface diseases.
Healome Therapeutics at a glance
Healome Therapeutics is a healthcare company headquartered in United Kingdom, founded in 2021. Its most recent funding round, Seed, raised $2.6M in July 2026. Xcout tracks 4 named people at Healome Therapeutics, including Richard Williams (Co-Founder and CEO).
Healome Therapeutics leadership
- Richard WilliamsCo-Founder and CEO
- Liam GroverCo-Founder
- Richard MoakesCo-Founder
- Tony MetcalfeCo-Founder
Healome Therapeutics funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $2.6M | 5 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Healome Therapeutics news
Top 12 Healome Therapeutics competitors
Ranked by semantic similarity — how close each company is to Healome Therapeutics by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar healthcare company
Vantage Biosciences is a clinical-stage biotechnology company headquartered in London, United Kingdom. Founded in 2023, the firm focuses primarily on advancements and clinical trials in the field of ophthalmology. It manages drug pipelines and pharmaceutical research out of its London office.
Similar healthcare company
SolasCure Limited is a biotechnology research company registered and headquartered in Cambridge, United Kingdom, focused on developing novel wound care solutions.
Similar healthcare company
Breye Therapeutics ApS is a biotechnology company committed to closing the gap in eye care by developing first-in-class oral small molecule therapies to treat retinal diseases. The company is advancing oral therapies like danegaptide for the early treatment of these conditions.
Similar healthcare company
Prokarium is a biotechnology research company headquartered in London, United Kingdom, focused on developing targeted immunotherapies like its investigational treatment ZH9.
Similar healthcare company
Ailomics Therapeutics, founded in 2022 and headquartered in Shanghai, China, is a therapeutics company focused on discovering novel targets.
Similar healthcare company
Oxular is a UK-based, clinical-stage biotechnology company that develops new treatments and delivery technologies for retinal diseases. The firm was acquired by Regeneron Pharmaceuticals in January 2025.
Similar healthcare company
Cellestial Health is a privately held therapeutics development company spun out from the University of Cambridge in 2023 to create new treatments for Parkinson's disease and related conditions.
Similar healthcare company
Oruka Therapeutics, Inc. is a biopharmaceutical company dedicated to developing novel biologics designed to establish a new treatment standard for chronic skin diseases.
Biotechnology
Eyebiotech Ltd is a clinical-stage biotechnology company headquartered in London, United Kingdom. Founded in 2021, the company focuses on developing novel therapies for ophthalmology and ocular diseases.
Biotechnology
MCAL Therapeutics Inc. is a biotechnology company developing synthetic, rabbit-inspired lipid eye drops and extended-release drug delivery platforms. Its lead candidate, MCAL-201, is designed to treat evaporative dry eye disease by restoring the tear film's protective lipid barrier.
Pharmaceuticals
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.
Biotech
Alkeus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing treatments that preserve the sight of individuals impacted by severe eye diseases.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Healome Therapeutics and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Healome Therapeuticsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →